SCHEMBL6794591

SCHEMBL6794591

NC(=O)c1cc(-c2ccccc2)c2c(n1)OCCN(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 7/20 0.46
NR1I2 O75469 1/20 0.46
KCNH2 Q12809 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
TNIK Q9UKE5 2/20 0.39
TACR1 P25103 6/20 0.37
ADRB2 P07550 1/20 0.37
FPR1 P21462 1/20 0.37
GPR183 P32249 1/20 0.37
APLNR P35414 1/20 0.37
GLP1R P43220 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
GPR35 Q9HC97 1/20 0.37
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6794230 0.93 ROCK2 (0.43) GRM2NR1I2KCNH2SIRT2SIRT1
SCHEMBL6789047 0.89 TACR1 (0.41) SIRT2SIRT1ROCK2ROCK1TACR1
SCHEMBL6797973 0.89 KDM4E (0.41) SIRT2SIRT1ROCK2ROCK1TNIK
SCHEMBL6789811 0.88 KDM4E (0.42) SIRT2SIRT1ROCK2ROCK1TNIK
SCHEMBL6795180 0.88 ROCK2 (0.40) SIRT2SIRT1ROCK2ROCK1TNIK
SCHEMBL6794467 0.87 TACR1 (0.42) KCNH2SIRT2SIRT1ROCK2ROCK1
SCHEMBL6794050 0.86 ROCK2 (0.44) SIRT2SIRT1ROCK2ROCK1TNIK
SCHEMBL6793859 0.85 ROCK2 (0.43) SIRT2SIRT1ROCK2ROCK1TNIK
SCHEMBL4513882 0.85 ROCK2 (0.44) SIRT2SIRT1ROCK2ROCK1TNIK
SCHEMBL6794992 0.84 TACR1 (0.40) ROCK2ROCK1TNIKTACR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6147071-A TACHYKININ RECEPTOR ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-11-14 US claimed
US-20040058914-A1 Combination drugs TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
US-20040023843-A1 Preventives/remedies for emotional disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-05 US disclosed
EP-1352659-A1 COMBINATION DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-10-15 EP disclosed
EP-1323429-A1 PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS Takeda Chemical Industries, Ltd. (JP) 2003-07-02 EP disclosed
EP-0733632-B1 Cyclic compounds, their production and use as tachykinin receptor antagonists TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-06-04 EP disclosed
US-6489315-B1 NOVEL CYCLIC COMPOUNDS HAVING AN EXCELLENT TACHYKININ RECEPTOR ANTAGONISTIC EFFECT, AND A METHOD FOR PRODUCING THEM, FOR TREATING DISORDERS OF INCONTINENCE, ASTHMA, MIGRAINE, IRRITABLE BOWEL SYNDROME, PAIN, COUGH OR EMESIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-12-03 US disclosed
US-20020132817-A1 Heterocyclic compounds, their production and use NATSUGARI HIDEAKI (JP) 2002-09-19 US disclosed
EP-1184036-A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists Takeda Chemical Industries, Ltd. (JP) 2002-03-06 EP disclosed
EP-1145714-A1 DRUGS Takeda Chemical Industries, Ltd. (JP) 2001-10-17 EP disclosed
CN-1291099-A Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-04-11 CN disclosed
US-6147071-A TACHYKININ RECEPTOR ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-11-14 US disclosed
EP-0733632-A1 Cyclic compounds, their production and use as tachykinin receptor antagonists Takeda Chemical Industries, Ltd. (JP) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023843-A1 Preventives/remedies for emotional disorders MTNR1A, KISS1R, MTNR1B GRM2 317/4885NR1I2 874/4885KCNH2 894/4885
US-20020132817-A1 Heterocyclic compounds, their production and use CRH, CRHR1, CRHR2 GRM2 186/4885NR1I2 256/4885KCNH2 550/4885
US-20040058914-A1 Combination drugs CHRNA1, CHRNA2, CHRM2 GRM2 308/4885NR1I2 207/4885KCNH2 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.